It was reported that hypoxia-inducible factor (HIF)1, advanced glycation end-products-dependent transcription factor, transforming growth factor (TGF)-, tolloid protein-1 (TLD1) and fibronectin all promoted either the expression or activation of LOX (33,84-89)
However, a review of recent studies indicates that this is soon to change as more clinicians become aware of the unique advantages of nasal delivery of peptides and other therapeutics
This requires frequent contact between the patient and the clinician
This approach delivers peptide directly to target tissues, bypassing skin absorption limitations entirely
invasion assay) were used as interface between the two compartments
This results in a lack of energy production from fatty acids, which causes symptoms ranging from tiredness and hypoglycemia (glucose being used extensively as an energy source) to accumulation of fat in the liver and other organs, and damage to heart and muscle tissues